Candel Therapeutics, Inc. CADL
9.29 USD +0.47 (+5.33%)
Nov 4, 2026, 9:48 AM EST
8.81 Day range 9.33
4.35 52-week range 14.00
- YTD
- +64.42%
- 1 year
- +81.09%
News
globenewswire.com Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients…
globenewswire.com Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
globenewswire.com Candel Therapeutics to Present at November Investor Conferences NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25 Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $25.
globenewswire.com Candel Therapeutics Appoints Maria Ostrovsky as General Counsel NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
globenewswire.com Candel Therapeutics to Present at the SITC 2026 Annual Meeting NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
globenewswire.com Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI. Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to…
globenewswire.com Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…- benzinga.com Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these…
globenewswire.com Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com Candel Therapeutics Presents New Biomarker Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients…
globenewswire.com Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
seekingalpha.com Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized prostate cancer. The company's aglatimagene met the primary endpoint in a pivotal trial, reducing…
benzinga.com This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded MAC, INVH, CIEN, AMH and CADL, raising ratings and several price targets.
benzinga.com B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18 B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.
zacks.com 4 Prostate Cancer Drug Stocks to Watch During Awareness Month Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
globenewswire.com Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
globenewswire.com Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
globenewswire.com Candel Therapeutics to Present at September Investor Conferences NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
seekingalpha.com Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO…- benzinga.com B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12 B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.
- benzinga.com Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over…
globenewswire.com Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
marketbeat.com Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief…
seekingalpha.com Candel Therapeutics: Getting Closer, And Building Out More Paths Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash,…
globenewswire.com Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
globenewswire.com Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…- benzinga.com Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22 Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.
benzinga.com Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembrolizumab In Participants With Metastatic Non-Squamous Non-Small Cell Lung Cancer Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients…- benzinga.com Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with…
benzinga.com Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.- benzinga.com Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in…
benzinga.com Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings…- benzinga.com Candel Therapeutics To Hold Conference Call On May 15 To Discuss Extended Follow-Up Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec In Participants With Intermediate- To High-Risk Localized Prostate Cancer Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with…
benzinga.com Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.
benzinga.com 10 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) (Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story. Figures from economic reports were added.) U.S. stock futures declined on Friday…
benzinga.com Akamai Technologies, Inseego, Ardelyx And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday 
benzinga.com EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session